What is Veradermics?
Veradermics is a clinical-stage biopharmaceutical enterprise dedicated to the discovery and development of novel therapeutic solutions for dermatologic and aesthetic conditions. The company distinguishes itself through a research-driven approach, prioritizing non-hormonal mechanisms to treat complex skin and hair-related pathologies. By focusing on oral delivery systems, Veradermics aims to improve patient compliance and therapeutic outcomes, positioning itself as a key innovator in a market traditionally dominated by topical or invasive procedures. Its market position is bolstered by a sophisticated intellectual property portfolio and a clear focus on translating academic discoveries into scalable, commercial-ready medical products.
How much funding has Veradermics raised?
Veradermics has raised a total of $616.3M across 4 funding rounds:
Series B
$75M
Series C
$150M
Stock/Share Issuance
$135M
IPO
$256.3M
Series B (2024): $75M with participation from J.W. Childs Associates, Suvretta Capital Management, Longitude Capital, Surveyor Capital, Connecticut Innovations, Osage University Partners, and PhiFund Ventures
Series C (2025): $150M led by Invus, SR One, Viking Global Investors, Infinitium, LifeSci Venture Partners, Longitude Capital, Columbia Threadneedle Investments US, Suvretta Capital Management, and Marshall Wace
Stock/Share Issuance (2025): $135M, investors not publicly disclosed
IPO (2026): $256.3M featuring Lilly and Wellington Management
Key Investors in Veradermics
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines, focusing on areas such as immunology and neuroscience.
Wellington Management
Wellington Management is a global, independent investment management firm providing institutional clients with research-intensive portfolio management and tailored investment solutions across diverse asset classes.
SR One
SR One is a transatlantic biotechnology venture capital firm that invests in early and growth-stage life sciences companies, leveraging deep sector expertise to translate innovative technologies into new medicines.
What's next for Veradermics?
Following the recent capital influx, Veradermics is poised to transition from a clinical-stage developer to a commercial-ready biopharmaceutical leader. The strategic roadmap likely involves the acceleration of late-stage clinical trials for its lead hair regrowth program, alongside the expansion of its internal R&D capabilities to explore additional dermatologic indications. With the support of high-profile institutional investors, the company is expected to prioritize regulatory filings and the establishment of a robust commercial infrastructure. This phase of development will be critical in validating the firm's long-term value proposition and ensuring the successful market entry of its flagship therapeutic candidates, ultimately aiming to redefine the standard of care in aesthetic medicine.
See full Veradermics company page
